Liposome capable of dynamically adjusting timolol release according to intraocular pressure and preparation method and application thereof

By using dynamically adjusted liposomes in timolol eye drops, using the combination of timolol base, phospholipids and cholesterol, the rapid release of timolol under high eye pressure is achieved, and after returning to normal The slow release solves the problem of low intraocular pressure caused by timolol eye drops, and improves the safety and user experience of the drug.

CN119055591APending Publication Date: 2024-12-03JIANGSU YUANHENG PHARMA +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411069116.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-06
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Long-term or large-scale use of timolol eye drops leads to a rapid drop in the intraocular pressure, causing adverse reactions such as visual field defects and iris color change, and inconvenient monitoring of patients, increasing safety risks.

Method used

Develop a timolol-releasing liposome that is dynamically adjusted according to intraocular pressure. Through the combination of timolol base, phospholipids and cholesterol, a pressure-sensitive liposome is formed, which is quickly released under high intraocular pressure. Tiemolol, slowly release after returning to normal, avoiding continuous decline.

Benefits of technology

It effectively solves the problem of low intraocular pressure caused by thimolol medication, ensures the safety and stability of intraocular pressure, reduces adverse reactions, and improves the patient's experience and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055591A_ABST
    Figure CN119055591A_ABST
Patent Text Reader

Abstract

The invention discloses a liposome capable of dynamically adjusting timolol release according to intraocular pressure as well as a preparation method and application of the liposome. The liposome comprises a timolol base, phospholipid, cholesterol and a timolol salt form. The phospholipid comprises one or more of 1-stearoyl-2-oleyl phosphatidylcholine, 1-oleoyl-2-palmitoyl phosphatidylcholine or 1-oleoyl-2-stearic acid phosphatidylcholine, and the phospholipid comprises one or more of 1-stearoyl-2-oleyl phosphatidylcholine, 1-oleoyl-2-palmitoyl phosphatidylcholine and 1-oleoyl-2- The problem that the intraocular pressure is too low due to the fact that the intraocular pressure is continuously reduced by the timolol maleate solution at the normal intraocular pressure is solved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of pharmaceuticals, and in particular relates to a liposome capable of dynamically adjusting the release of timolol according to intraocular pressure, and a preparation method and application thereof. Background Art

[0002] Timolol is a beta-adrenergic receptor blocker. Timolol maleate eye drops can inhibit the production of aqueous humor and reduce intraocular pressure. However, when used for a long time or in large quantities, the intraocular pressure may drop too quickly, thereby causing adverse reactions such as visual field defects and iris color changes. Therefore, during the use of timolol maleate eye drops, regular monitoring of intraocular pressure is usually required to ensure the safe use of the drug. This not only brings many inconveniences to patients and increases the burden on patients, but is also prone to safety hazards of medication due to patients' non-cooperation with intraocular pressure monitoring. Therefore, how to avoid excessive decreases in intraocular pressure caused by timolol medication is an important issue that needs to be addressed.

[0003] The invention discloses a liposome capable of dynamically adjusting the release of timolol by intraocular pressure, a preparation method and an application thereof. The liposome can rapidly release timolol under the action of high intraocular pressure to reduce the intraocular pressure; when the intraocular pressure returns to normal, the liposome slowly releases the drug, thereby avoiding the continuous decrease of the intraocular pressure caused by the drug. Summary of the invention

[0004] The purpose of this section is to summarize some aspects of embodiments of the present invention and to briefly introduce some preferred embodiments.

[0005] As one aspect of the present invention, the present invention provides a liposome that dynamically adjusts the release of timolol according to intraocular pressure, wherein: the liposome includes timolol base, phospholipids, cholesterol, and timolol salt; the phospholipids include one or more of 1-stearoyl-2-oleoylphosphatidylcholine, 1-oleoyl-2-palmitoylphosphatidylcholine or 1-oleoyl-2-stearoylphosphatidylcholine.

[0006] As a preferred embodiment of the liposomes for dynamically adjusting the release of timolol according to intraocular pressure of the present invention, the mass ratio of timolol base to phospholipid is 1:1.5-1:3; the mass ratio of phospholipid to cholesterol is 3:1-5:1.

[0007] As a preferred embodiment of the liposomes for dynamically adjusting the release of timolol according to the intraocular pressure described in the present invention: the timolol salt type includes one or more of the maleate, tartrate, hydrochloride, sulfate, acetate, hydrofluoride and nitrate of timolol.

[0008] As a preferred embodiment of the liposomes for dynamically adjusting the release of timolol according to the intraocular pressure of the present invention: the particle size of the liposomes is 600-900 nm.

[0009] As another aspect of the present invention, the present invention also provides a method for preparing the liposomes that dynamically adjust the release of timolol according to intraocular pressure: dissolving the timolol base, phospholipids and cholesterol in a solvent to form a mixed solution, rotary evaporating and vacuuming to form a thin film, adding physiological saline containing timolol salt to hydrate and form liposomes.

[0010] As a preferred embodiment of the method for preparing liposomes capable of dynamically adjusting the release of timolol according to intraocular pressure of the present invention: the solvent comprises one or more of dichloromethane, chloroform, ethanol, acetone and ethyl acetate.

[0011] As a preferred embodiment of the method for preparing liposomes capable of dynamically adjusting the release of timolol according to intraocular pressure of the present invention, the concentration of phospholipids in the solvent is 80-120 mg / mL.

[0012] As a preferred embodiment of the method for preparing liposomes capable of dynamically adjusting the release of timolol according to intraocular pressure of the present invention, the concentration of timolol salt in physiological saline is 10-50 mg / mL.

[0013] Beneficial effects of the present invention: The present invention solves the adverse reaction of hypotension caused by the continuous reduction of intraocular pressure caused by timolol maleate solution under normal intraocular pressure. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the following briefly introduces the drawings required for describing the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative labor. Among them:

[0015] Figure 1 This is the particle size distribution diagram of timolol liposomes.

[0016] Figure 2 This is a transmission electron micrograph of timolol liposomes.

[0017] Figure 3 Schematic diagram of the loop device for in vitro release of timolol liposomes.

[0018] Figure 4 Effect of phospholipid species on the pressure sensitivity of timolol liposomes.

[0019] Figure 5Effect of the mass ratio of timolol base to phospholipids dissolved in dichloromethane on the pressure sensitivity of timolol liposomes.

[0020] Figure 6 The release behaviors of timolol liposomes under different pressures in Example 1 and Comparative Example 1 are shown.

[0021] Figure 7 The effect of timolol liposomes in Example 1 on the intraocular pressure of rabbits with acute ocular hypertension. DETAILED DESCRIPTION

[0022] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the specific implementation methods of the present invention are described in detail below in conjunction with specific embodiments.

[0023] Embodiment 1:

[0024] Preparation of timolol pressure-sensitive liposomes: 40 mg of timolol base (Aladdin, catalog number: T614458), 100 mg of 1-stearoyl-2-oleoylphosphatidylcholine (SOPC) and 25 mg of cholesterol were dissolved in 1 mL of dichloromethane to form a mixed solution of timolol base, SOPC and cholesterol, which was vacuumed at 50 ° C in a rotary evaporator to form a thin film. The film was hydrated by adding 5 mL of physiological saline containing 20 mg / mL of timolol maleate to form liposomes. The unencapsulated timolol maleate was removed by ultrafiltration centrifuge tube with a molecular weight cutoff of 10 kDa, and the timolol was diluted to 3.7 mg / mL (equivalent to 5 mg / mL of timolol maleate) with physiological saline to obtain the final timolol liposomes.

[0025] Comparative Example 1:

[0026] 100 mg of egg yolk lecithin and 50 mg of cholesterol were dissolved in 1 mL of dichloromethane to form a mixed solution of egg yolk lecithin and cholesterol, which was vacuumed at 50°C in a rotary evaporator to form a thin film. 5 mL of normal saline (containing 20 mg / mL of timolol maleate) was added to the film to hydrate it to form liposomes. The unencapsulated timolol maleate was removed by ultrafiltration centrifuge tube with a molecular weight cutoff of 10 kDa, and timolol was diluted to 3.7 mg / mL (equivalent to 5 mg / mL of timolol maleate) with normal saline to obtain the final liposomes.

[0027] Comparative Example 2:

[0028] Dissolve 25 mg of timolol maleate in 5 mL of normal saline and filter through a 0.22 μm microporous filter to prepare 5 mg / mL timolol maleate eye drops.

[0029] Embodiment 2:

[0030] Liposome particle size detection and morphology observation:

[0031] The liposomes prepared in Example 1 were diluted with 50 times the volume of physiological saline and the particle size was measured in a particle size analyzer (NanoBrook 173 Plus, Brookhaven). The particle size distribution is as follows: Figure 1 As shown, the average particle size is 751.9 nm.

[0032] The morphology was observed by transmission electron microscopy. Figure 2 As shown, its shape is spherical or ellipsoidal, and its particle size range is consistent with Figure 1 Observation results.

[0033] Embodiment 3:

[0034] Timolol liposome release assay:

[0035] Take 10 mL of timolol liposomes, add 500 mL of normal saline (containing 1% Tween-80), and use a peristaltic pump to allow the liposome dilution to enter the loop connected to the pressure gauge, flow meter and valve ( Figure 3 As shown). The hydrostatic pressure of the release circuit is controlled by controlling the flow rate of the peristaltic pump and the opening and closing size of the valve. Samples are taken at regular intervals, passed through an ultrafiltration centrifuge tube with a molecular weight cutoff of 10 kDa, and the ultrafiltrate is taken. The timolol content is detected by HPLC, and the drug release amount is calculated.

[0036] Embodiment 4:

[0037] Effect of phospholipid types on the pressure sensitivity of timolol liposomes:

[0038] 40 mg of timolol base, 100 mg of phospholipids and 25 mg of cholesterol were dissolved in 1 mL of dichloromethane to form a mixed solution of timolol base, phospholipids and cholesterol, which was vacuumed at 50°C in a rotary evaporator to form a thin film. 5 mL of normal saline (containing 20 mg / mL of timolol maleate) was added to the film to hydrate it to form liposomes. The liposomes were removed by ultrafiltration centrifuge tubes with a molecular weight cutoff of 10 kDa to obtain the final liposomes. The phospholipids used are 1-stearoyl-2-oleoylphosphatidylcholine (SOPC), 1-oleoyl-2-palmitoylphosphatidylcholine (OPPC), 1-oleoyl-2-stearoylphosphatidylcholine (OSPC), 1-stearoyl-2-palmitoylphosphatidylcholine (SPPC), 1-stearoyl-2-myristoylphosphatidylcholine (SMPC) or mixed phospholipids (SOPC: OPPC: OSPC = 1: 1: 1, W / W / W).

[0039] The drug release of the prepared liposomes was tested according to the method of Example 4 at 0 kPa pressure, 1.5 kPa pressure and 3.0 kPa pressure for half an hour. Figure 4It shows that the timolol liposomes prepared by using several phospholipids release almost no drug within half an hour under 0 kPa pressure. The liposomes prepared by using SOPC, OPPC, OSPC and mixed phospholipids (SOPC: OPPC: OSPC = 1: 1: 1, W / W / W) release more than 25% of timolol within half an hour under 1.5 kPa pressure, and more than 30% of timolol at 3.0 kPa, indicating that the timolol liposomes prepared by these phospholipids have obvious pressure-sensitive drug release behavior. The liposomes prepared by using SPPC or SMPC release less than 10% of the drug under 1.5 or 3.0 kPa pressure. The inferred principle may be that SOPC, OPPC and OSPC have lower phase transition temperatures (6, -9 and 9 ° C, respectively), while the phase transition temperatures of SPPC and SMPC are 44 and 30 ° C. The lower phase transition temperature makes the formed liposomes have a softer membrane structure, which is more likely to rupture and release drugs under pressure. Therefore, in the preferred method for preparing liposomes for dynamically adjusting the release of timolol according to intraocular pressure of the present invention, the phospholipid dissolved in dichloromethane is preferably one or more of SOPC, OPPC, and OSPC.

[0040] Embodiment 5:

[0041] Effect of the mass ratio of timolol base to phospholipids on the pressure sensitivity of timolol liposomes:

[0042] An appropriate amount of timolol base, 100 mg SOPC and 25 mg cholesterol were dissolved in 1 mL of dichloromethane to form a mixed solution of timolol base, phospholipids and cholesterol, which was vacuumed at 50 °C in a rotary evaporator to form a thin film. The film was hydrated by adding 5 mL of normal saline (containing 20 mg / mL timolol maleate) to form liposomes. The unencapsulated timolol maleate was removed by ultrafiltration centrifuge tube with a molecular weight cutoff of 10 kDa to obtain the final liposomes. The input mass of timolol base was set to 100, 67, 50, 40, 33, 29, and 0 mg, respectively, so that the mass ratio of timolol to SOPC reached 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5 and 0, respectively.

[0043] The drug release of the prepared liposomes was tested according to the method of Example 4 at 0 kPa pressure, 1.5 kPa pressure and 3.0 kPa pressure for half an hour. Figure 5It shows that when the mass ratio of timolol base to phospholipid is 1:1, even under 0kPa pressure, the drug release amount of liposomes can exceed 25% within half an hour, and the drug release amount does not increase significantly after increasing the pressure. When the mass ratio of timolol base to phospholipid is between 1:1.5 and 1:3, the formed timolol liposomes have obvious pressure-triggered drug release characteristics. When the mass ratio of timolol base to phospholipid is reduced to 1:3.5 and 0, the pressure-sensitive properties of the liposomes gradually disappear due to the decrease in the proportion of timolol base in the liposome membrane. This phenomenon indicates that the distribution of timolol base in the liposome membrane is crucial to the pressure-sensitive drug release properties of the liposome, which may be because the distribution of timolol base in the liposome membrane disrupts the orderly arrangement of the phospholipid bilayer, thereby reducing the interaction force between phospholipids, which further leads to the rupture and drug release of the liposome under a specific hydrostatic pressure. Therefore, the input mass ratio of timolol base dissolved in dichloromethane to phospholipids in the liposome membrane should be between 1:1.5 and 1:3.

[0044] Embodiment 6:

[0045] Effect of phospholipid concentration in dichloromethane on the pressure sensitivity of timolol liposomes:

[0046] According to the prescription in Table 1, a certain amount of timolol base, phospholipids and cholesterol were dissolved in 1 mL of dichloromethane to form a mixed solution of timolol base, phospholipids and cholesterol, and a film was formed by vacuuming at 50°C in a rotary evaporator. The film was hydrated by adding 5 mL of normal saline (containing 20 mg / mL of timolol maleate) to form liposomes. The mass ratio of timolol base, SOPC and cholesterol in dichloromethane was kept constant, and the phospholipid concentration in dichloromethane was gradually increased from 40 mg / mL to 160 mg / mL. As shown in Table 1, when the phospholipid concentration in dichloromethane was between 40-60 mg / mL, the liposome particle size was between 200-400 nm, and the liposome had no obvious pressure-sensitive properties. When the phospholipid concentration in dichloromethane was between 80-120 mg / mL, the liposome particle size was between 600-900 nm, and the liposome had obvious pressure-sensitive properties. When the concentration of phospholipids in dichloromethane exceeds 120mg / mL, the liposome particle size is greater than 900nm, and the liposome is unstable at this time, and obvious drug leakage occurs under 0kPa. The above results show that the concentration of phospholipids in dichloromethane determines the liposome particle size. When the particle size is too low, the liposome is more stable and has no pressure sensitivity, while the liposome with too large particle size is unstable and prone to drug leakage. Therefore, the concentration of phospholipids in dichloromethane is preferably 80-120mg / mL, and the liposome particle size is preferably 600-900nm.

[0047] Table 1 Effect of phospholipid concentration in dichloromethane on the pressure sensitivity of timolol liposomes

[0048]

[0049] Embodiment 7:

[0050] Effect of the mass ratio of phospholipids to cholesterol on the pressure sensitivity of timolol liposomes:

[0051] 40 mg of timolol base, 100 mg of SOPC and a certain amount of cholesterol were dissolved in 1 mL of dichloromethane to form a mixed solution of timolol base, SOPC and cholesterol, which was vacuumed at 50 ° C in a rotary evaporator to form a film. 5 mL of normal saline (containing 20 mg / mL of timolol maleate) was added to the film to form liposomes. The unencapsulated timolol maleate was removed by ultrafiltration centrifuge tube with a molecular weight cutoff of 10 kDa to obtain the final liposomes. The amount of cholesterol added was changed to 100, 50, 33, 25, 20, and 16.7 mg, respectively, to obtain samples with a mass ratio of SOPC to cholesterol of 1:1, 2:1, 3:1, 4:1, 5:1 and 6:1, respectively. Particle size measurement and drug release test under different pressures were performed, and the results are shown in Table 2. From this result, it can be seen that when the mass ratio of phospholipids to cholesterol is 1:1 and 2:1, the drug release in 30 minutes at 1.5kPa is less than 10%, and when the mass ratio of phospholipids to cholesterol is 6:1, no stable liposomes are formed. When the mass ratio of phospholipids to cholesterol is in the range of 3:1 to 5:1, the particle size of the liposomes formed is between 600-900nm, and there is an obvious burst release of the drug at 1.5kPa. Therefore, the mass ratio of phospholipids to cholesterol is preferably 3:1 to 5:1.

[0052] Table 2 Effect of phospholipid to cholesterol mass ratio on particle size and pressure sensitivity of timolol liposomes

[0053]

[0054] Embodiment 8:

[0055] Effect of timolol maleate concentration in hydrated saline on drug loading, encapsulation efficiency and pressure sensitivity of liposomes:

[0056] 40 mg of timolol base, 100 mg of SOPC and 40 mg of cholesterol were dissolved in 1 mL of dichloromethane to form a mixed solution of timolol base, SOPC and cholesterol, which was vacuumed at 50 ° C in a rotary evaporator to form a film. The film was hydrated by adding 5 mL of normal saline (containing different concentrations of timolol maleate) to form liposomes. The unencapsulated timolol maleate was removed by passing through an ultrafiltration centrifuge tube with a molecular weight cutoff of 10 kDa to obtain the final liposomes. The concentrations of timolol maleate in the normal saline were 1, 5, 10, 20, and 40 mg / mL, respectively, to obtain different samples. The encapsulation efficiency, drug loading and drug release tests under different pressures were performed. The encapsulation efficiency and drug loading were determined by diluting the liposomes with 10 times the volume of 2% Tween-80 normal saline solution, centrifuging using an ultrafiltration centrifuge tube with a molecular weight cutoff of 10 kDa, taking the ultrafiltrate, and determining the timolol concentration in the ultrafiltrate, which was the unencapsulated timolol concentration. The encapsulation efficiency and drug loading were calculated according to Formula 1, Formula 2 and Formula 3.

[0057]

[0058]

[0059] The results are shown in Table 3. From this result, it can be seen that when the concentration of timolol maleate in hydrated saline is 1-20 mg / mL, the liposome encapsulation rate exceeds 80%, because the fat-soluble timolol base is almost completely encapsulated in the lipid membrane of the liposome, and this part of the drug improves the encapsulation rate of the overall drug; and when the concentration of timolol maleate in hydrated saline reaches 40 mg / mL, the encapsulation rate is reduced to 55%, because the amount of timolol maleate in the saline far exceeds the amount of timolol base encapsulated in the lipid membrane of the liposome, and the timolol maleate in the aqueous phase is difficult to be encapsulated, so the liposome encapsulation rate is significantly reduced. The above results show that the concentration of timolol maleate in hydrated saline should be lower than 40 mg / mL.

[0060] From the results of pressure-sensitive drug release, when the concentration of timolol maleate in hydrated saline was 1 mg / mL, the drug release of liposomes under 1.5 kPa pressure within 30 minutes was only 5%, while when the concentration of timolol maleate in hydrated saline was 5, 10, and 20 mg / mL, the drug release of liposomes under 1.5 kPa pressure within 30 minutes could reach 19%, 28%, and 39%. This may be because the pressure sensitivity of liposomes is due to the structural rupture of liposomes under a certain hydrostatic pressure, and the drug in the inner water is released in large quantities. When the amount of timolol maleate encapsulated in the inner water is small, the rupture of liposomes cannot produce enough drug release.

[0061] Based on the experimental results of drug encapsulation efficiency, drug loading and pressure sensitivity, the preferred concentration of timolol maleate in hydrated saline is 5-20 mg / mL.

[0062] Table 3 Effect of timolol maleate concentration in hydrated saline on liposome drug loading, encapsulation efficiency and pressure sensitivity

[0063]

[0064]

[0065] Embodiment 9:

[0066] Release behavior of timolol liposomes under different pressures:

[0067] The release of the timolol liposomes prepared in Example 1 and Comparative Example 1 was measured at 0 kPa, 0.5 kPa, 1.5 kPa and 3.0 kPa pressures, respectively. Figure 6 As can be seen from the figure, the liposomes prepared in the example can slowly release the drug under the pressure of 0 and 0.5 kPa, and can quickly release the drug under the pressure of 1.5 and 3.0 kPa. The liposomes prepared in Comparative Example 1, under the pressure of 0-3.0 kPa, the drug release percentage within 10 hours is less than 30%. The above results prove that the preparation method disclosed in the present invention can obtain timolol liposomes with pressure-responsive drug release ability.

[0068] Embodiment 10:

[0069] Particle size changes of timolol liposomes under different pressures:

[0070] The timolol liposomes prepared in Example 1 and Comparative Example 1 were treated with 0kPa, 0.5kPa, 1.5kPa and 3.0kPa pressures for 30 minutes, respectively, and the results of measuring the sample particle size are shown in Table 4. As can be seen from the results, the particle size of the liposomes in Comparative Example 1 did not change significantly after being treated with different pressures for 30 minutes. However, after the liposomes in Example 1 were treated with 1.5kPa pressure for 30 minutes, the particle size increased significantly, which was due to the rupture of the liposomes and the flocculation of the broken liposomes, resulting in an increase in the particle size measurement value; after the 3.0kPa pressure treatment for 30 minutes, the liposomes in Example 1 were significantly turbid, resulting in the inability to measure the particle size, which was due to the rupture of the liposomes producing a large amount of flocculation. The above results further prove that the liposomes prepared in Example 1 have a mechanism of pressure-responsive drug release, which is that the liposomes undergo structural rupture under pressure, thereby rapidly releasing the drug.

[0071] Table 4 Particle size changes of timolol liposomes after treatment at different pressures for 30 minutes

[0072]

[0073]

[0074] Embodiment 11:

[0075] Effect of timolol liposomes on intraocular pressure in rabbits with acute ocular hypertension in Example 1:

[0076] Twelve female rabbits were randomly divided into 4 groups: normal saline group, comparative example 2 (timolol maleate solution) group, comparative example 1 (timolol maleate ordinary liposome) group, and example 1 (timolol pressure-sensitive liposome) group. The four groups of rabbits were anesthetized with urethane, and the intraocular pressure was measured by tonometer, which was measured once every 10 minutes, and the normal basal value of intraocular pressure was obtained by continuous measurement for 3 times. 5% glucose (15mL / kg) was rapidly injected into the ear vein of the rabbit within 1 minute to induce acute intraocular hypertension. After the injection, the samples from each group were immediately used for eye drops, with 3 drops in each eyeball. The intraocular pressure was measured once 5, 10, 20, 30, 45, 60, 90, and 120 minutes after the end of administration. The results are as follows Figure 7 As shown, after the rabbit ear vein was injected with glucose solution, the intraocular pressure increased rapidly. The intraocular pressure of the rabbit given normal saline was maintained at a high level within 8 hours, and was reduced until 12 hours. After giving the common liposomes of timolol maleate prepared in Comparative Example 1, the intraocular pressure of the rabbit gradually decreased, but the rate of decline was slower than that of the timolol maleate solution prepared in Comparative Example 2, which may be due to the slow release of the common liposome drug prepared in Comparative Example 1. After giving the timolol pressure-sensitive liposomes prepared in Example 1, the intraocular pressure of the rabbit decreased rapidly, and its rate of decline was no significant difference with the comparative example 2 group within 4 hours. However, unlike Comparative Example 2 (timolol maleate solution), the Example 1 group maintained the intraocular pressure of the rabbits near the normal physiological baseline value after 4 hours, avoiding the continuous decrease in intraocular pressure caused by the timolol maleate solution (as shown in the results of the Comparative Example 2 group after 4 hours). This is because the timolol liposomes prepared in Example 1 can quickly release the drug under higher pressure. When the intraocular pressure of the rabbits returns to normal, the drug release of the liposomes slows down, thereby avoiding the adverse reaction of low intraocular pressure caused by the timolol maleate solution.

[0077] It should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solutions of the present invention can be modified or replaced by equivalents without departing from the spirit and scope of the technical solutions of the present invention, which should be included in the scope of the claims of the present invention.

Claims

1. A liposome that dynamically adjusts the release of timolol according to intraocular pressure, characterized in that: The liposome comprises timolol base, phospholipid, cholesterol and timolol salt; the phospholipid comprises one or more of 1-stearoyl-2-oleoylphosphatidylcholine, 1-oleoyl-2-palmitoylphosphatidylcholine or 1-oleoyl-2-stearoylphosphatidylcholine.

2. The liposome for dynamically adjusting the release of timolol according to intraocular pressure according to claim 1, characterized in that: The mass ratio of timolol base to phospholipid is 1:1.5-1:3; the mass ratio of phospholipid to cholesterol is 3:1-5:

1.

3. The liposome for dynamically adjusting the release of timolol according to intraocular pressure according to claim 1 or 2, characterized in that: The timolol salt type includes one or more of timolol maleate, tartrate, hydrochloride, sulfate, acetate, hydrofluoride and nitrate.

4. The liposome for dynamically adjusting the release of timolol according to intraocular pressure according to claim 1 or 2, characterized in that: The particle size of the liposome is 600-900 nm.

5. The method for preparing the liposome capable of dynamically adjusting the release of timolol according to intraocular pressure according to claim 1, characterized in that: The timolol base, phospholipid and cholesterol are dissolved in a solvent to form a mixed solution, which is then rotary evaporated and vacuumed to form a thin film, and physiological saline containing timolol salt is added to hydrate the solution to form liposomes.

6. The method for preparing liposomes capable of dynamically adjusting the release of timolol according to intraocular pressure according to claim 5, characterized in that: The solvent includes one or more of dichloromethane, chloroform, ethanol, acetone, and ethyl acetate.

7. The method for preparing liposomes capable of dynamically adjusting the release of timolol according to intraocular pressure according to claim 5 or 6, characterized in that: The concentration of phospholipids in the solvent is 80-120 mg / mL.

8. The method for preparing liposomes capable of dynamically adjusting the release of timolol according to intraocular pressure according to claim 5 or 6, characterized in that: The concentration of timolol salt in normal saline is 10-50 mg / mL.

9. Use of the liposomes for dynamically adjusting the release of timolol according to intraocular pressure as claimed in claim 1 in ocular medicine.

10. The use according to claim 9, characterized in that: The ocular medicine includes eye drops.